As previously reported, Argus upgraded Silk Road Medical to Buy from Hold with a $24 price target. The company is expanding its commercial footprint by enlarging its sales force, extending patient access through broader CMS coverage, and extending to markets in China and Japan, the analyst tells investors in a research note. The firm adds that the company’s TransCarotid Artery Revascularization – TCAR – procedure reduces the risk of ischemic stroke in patients with carotid artery disease, and the addressable market for TCAR is “large and underpenetrated.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical expands TCAR portfolio with launch of tapered ENROUTE system
- Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System
- Silk Road Medical price target raised to $23 from $20 at Stifel
- Silk Road Medical price target raised to $28 from $20 at Lake Street
- Silk Road Medical price target raised to $18 from $11 at Piper Sandler
